AlphaVax Initiates Chlamydia Vaccine Program
US-based clinical-stage company AlphaVax has initiated a Chlamydia vaccine program based on its alphavirus vector platform technology.
AlphaVax will initiate studies on a prototype vaccine in collaboration with Luis de la Maza, professor of pathology and laboratory medicine at the University of California, Irvine. Dr Maza’s laboratory has established an animal model of chlamydial genital disease.
Robert Olmsted, vice president of research at AlphaVax, said: “This new program targeting a bacterial infectious disease complements well our alphavirus vector-based viral vaccine programs targeting influenza and cytomegalovirus where we are accumulating promising clinical results.”